Literature DB >> 8212557

Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells.

R E Lanford1, L Notvall, D Chavez, R White, G Frenzel, C Simonsen, J Kim.   

Abstract

The baculovirus/insect cell expression system was used to express the capsid protein and glycoproteins (e1 and e2/NS1) of the hepatitis C virus (HCV). Each polypeptide domain was expressed individually using two different constructs varying at their carboxy termini in order to retain or delete hydrophobic domains that may be involved in membrane association. The capsid proteins were transported to the nucleus where they formed a single large crystal-like inclusion. The capsid proteins were phosphorylated in insect cells. The e1 and e2 polypeptides were present in both the soluble and insoluble cellular fractions. Deletion of a hydrophobic domain in the carboxy terminus of e2 resulted in the polypeptide becoming soluble but not secreted. Deletion of the carboxy terminus of e1 had no effect on solubility. Both e1 and e2 were glycosylated, with variable glycosylation of e1 giving rise to a series of polypeptides varying in apparent molecular weight. Co-infection of insect cells with viruses expressing e1 and e2 resulted in a complex that permitted the coimmunoprecipitation of e1 with antibodies to e2 and vice versa. Immunofluorescence staining of insect cells expressing e1 and e2 indicated that reactivity to e2 was more prevalent in anti-HCV positive human sera.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212557     DOI: 10.1006/viro.1993.1583

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  Hepatitis C virus envelope proteins bind lactoferrin.

Authors:  M Yi; S Kaneko; D Y Yu; S Murakami
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.

Authors:  L M Lagging; K Meyer; R J Owens; R Ray
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins.

Authors:  A Choukhi; S Ung; C Wychowski; J Dubuisson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Hepatitis C virus structural proteins assemble into viruslike particles in insect cells.

Authors:  T F Baumert; S Ito; D T Wong; T J Liang
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Folding of hepatitis C virus E1 glycoprotein in a cell-free system.

Authors:  M Merola; M Brazzoli; F Cocchiarella; J M Heile; A Helenius; A J Weiner; M Houghton; S Abrignani
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

7.  The native form and maturation process of hepatitis C virus core protein.

Authors:  K Yasui; T Wakita; K Tsukiyama-Kohara; S I Funahashi; M Ichikawa; T Kajita; D Moradpour; J R Wands; M Kohara
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus.

Authors:  R Ray; A Khanna; L M Lagging; K Meyer; Q L Choo; R Ralston; M Houghton; P R Becherer
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.

Authors:  S E Bassett; D L Thomas; K M Brasky; R E Lanford
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies.

Authors:  J W Lee; K m Kim; S H Jung; K J Lee; E C Choi; Y C Sung; C Y Kang
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.